{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+%28TDF%29&page=2",
    "query": {
      "intervention": "Tenofovir (TDF)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+%28TDF%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T01:37:30.071Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05457530",
      "title": "Doravirine and Weight Gain in Antiretroviral Naive",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Body Weight Changes",
        "Human Immunodeficiency Virus",
        "ART",
        "Obesity",
        "Minority Health",
        "BMD",
        "Metabolic Syndrome",
        "Fasting"
      ],
      "interventions": [
        {
          "name": "DOR/3TC/TDF",
          "type": "DRUG"
        },
        {
          "name": "DOR + FTC/TAF",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Prism Health North Texas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2022-08-01",
      "completion_date": "2023-05-03",
      "has_results": false,
      "last_update_posted_date": "2023-05-12",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05457530"
    },
    {
      "nct_id": "NCT00117676",
      "title": "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "ADV",
          "type": "DRUG"
        },
        {
          "name": "TDF placebo",
          "type": "DRUG"
        },
        {
          "name": "ADV placebo",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 382,
      "start_date": "2005-02",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 17,
      "location_summary": "La Jolla, California • Pasadena, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00117676"
    },
    {
      "nct_id": "NCT01781806",
      "title": "A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "emtricitabine 200mg/tenofovir 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 328,
      "start_date": "2013-05",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01781806"
    },
    {
      "nct_id": "NCT03284164",
      "title": "Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "Tenofovir Exalidex (TXL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ContraVir Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2017-09-28",
      "completion_date": "2018-02-20",
      "has_results": false,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03284164"
    },
    {
      "nct_id": "NCT00799864",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "Rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Abacavir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Sciences Ireland UC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 54,
      "start_date": "2011-01",
      "completion_date": "2022-08",
      "has_results": true,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 2,
      "location_summary": "Syracuse, New York • Memphis, Tennessee",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00799864"
    },
    {
      "nct_id": "NCT02831764",
      "title": "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine (3TC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 722,
      "start_date": "2016-07-18",
      "completion_date": "2022-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-12-07",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831764"
    },
    {
      "nct_id": "NCT00605384",
      "title": "A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Entecavir + Tenofovir",
          "type": "DRUG"
        },
        {
          "name": "Adefovir + continuing Lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2008-08",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2010-11-23",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00605384"
    },
    {
      "nct_id": "NCT00384904",
      "title": "Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Atazanavir/Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir/Ritonavir + Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2006-12",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2010-02-05",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 3,
      "location_summary": "Voorhees Township, New Jersey • Chapel Hill, North Carolina • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Voorhees Township",
          "state": "New Jersey"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00384904"
    },
    {
      "nct_id": "NCT01080820",
      "title": "A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "CMX157",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Viread",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2010-06",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2011-07-04",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01080820"
    },
    {
      "nct_id": "NCT02556268",
      "title": "Interaction With HIV Antiretroviral Agents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-DDI"
      ],
      "interventions": [
        {
          "name": "Riociguat (Adempas, BAY 63-2521)",
          "type": "DRUG"
        },
        {
          "name": "ATRIPLA",
          "type": "DRUG"
        },
        {
          "name": "COMPLERA",
          "type": "DRUG"
        },
        {
          "name": "STRIBILD",
          "type": "DRUG"
        },
        {
          "name": "TRIUMEQ",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral protease inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2016-02-23",
      "completion_date": "2016-12-07",
      "has_results": false,
      "last_update_posted_date": "2017-12-06",
      "last_synced_at": "2026-09-29T01:37:30.071Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02556268"
    }
  ]
}